<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00467350</url>
  </required_header>
  <id_info>
    <org_study_id>06-07-117</org_study_id>
    <nct_id>NCT00467350</nct_id>
  </id_info>
  <brief_title>Comparison Trial of Enema vs. PEG 3350 for Constipation</brief_title>
  <official_title>Randomized Clinical Trial of Milk and Molasses Enema vs. PEG 3350 for Fecal Impaction in Childhood Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Mercy Hospital Kansas City</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Mercy Hospital Kansas City</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if milk and molasses enema or PEG 3350 works better&#xD;
      for treatment of fecal impaction in children who are constipated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Constipation is a common condition in childhood and occurs without evidence of a pathological&#xD;
      condition in most children. Symptoms range from decreased appetite to abdominal pain and&#xD;
      constipation is frequently diagnosed in children evaluated in emergency departments. A&#xD;
      general guideline for constipation treatment is fecal impaction removal before initiation of&#xD;
      maintenance therapy. Disimpaction may be achieved using various oral therapies (e.g.&#xD;
      including Polyethylene Glycol 3350 or PEG); however, rectal therapies, most commonly enemas,&#xD;
      are frequently used, especially in the emergency/urgent care setting. The optimal treatment&#xD;
      has not been established. There are no published randomized studies that compare&#xD;
      effectiveness of oral versus rectal treatments.&#xD;
&#xD;
      Comparison: One milk and molasses enema given to the patient in the emergency department&#xD;
      compared to three oral doses of PEG 3350 for relief of symptoms due to fecal impaction and&#xD;
      constipation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    concern patients in oral cleaout arm had worse outcome&#xD;
  </why_stopped>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Participants With Main Symptom Improvement</measure>
    <time_frame>5 days</time_frame>
    <description>On day 5, the number of participants who respond &quot;improved&quot; to the question &quot;Has your child's main symptom improved, stayed the same or gotten worse?&quot;</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Constipation</condition>
  <arm_group>
    <arm_group_label>enema</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rectal enema containing mixture of milk and molasses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG 3350</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medication to be taken orally once each day for three consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG 3350</intervention_name>
    <description>PEG 3350 1.5 gram/kg for disimpaction then 0.8 gram/kg for maintenance</description>
    <arm_group_label>PEG 3350</arm_group_label>
    <other_name>Miralax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>milk and molasses enema</intervention_name>
    <description>enema 10 cc/kg per rectum (max 500 cc)then PEG 3350 0.8 gram/kg for maintenance</description>
    <arm_group_label>enema</arm_group_label>
    <other_name>enema</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Constipated children who have one of the following three conditions:&#xD;
&#xD;
               -  Fecal impaction (lower quadrant mass or dilated rectum with hard stool),&#xD;
&#xD;
               -  Functional fecal retention (large diameter stools as determined by caregiver&#xD;
                  &lt;twice/week and retentive behaviors, or&#xD;
&#xD;
               -  Excessive stool in colon on abdominal radiograph as determined by attending&#xD;
                  radiologist or treating physician&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ill appearing patients (signs of acute surgical abdomen, abnormal vital signs, or&#xD;
             overall ill appearing as determined by treating physician)&#xD;
&#xD;
          -  Patients whose evaluation in the ED includes more than plain radiographs or urinalysis&#xD;
&#xD;
          -  Patients who receive analgesia for the abdominal pain in the ED (except acetaminophen&#xD;
             or ibuprofen)&#xD;
&#xD;
          -  Non-English speaking patients and families&#xD;
&#xD;
          -  Patients with milk allergy&#xD;
&#xD;
          -  Patients with molasses allergy&#xD;
&#xD;
          -  Patients who are pregnant&#xD;
&#xD;
          -  Patients with a chronic medical conditions which may be associated with constipation&#xD;
             (including patients with cystic fibrosis, cerebral palsy, hypothyroidism, spinal&#xD;
             anomalies, and known gastrointestinal anatomic abnormalities) or a history of prior&#xD;
             abdominal or rectal surgery&#xD;
&#xD;
          -  Patients who are admitted to an in-patient unit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melissa K Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Mercy Hospital Kansas City</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 26, 2007</study_first_submitted>
  <study_first_submitted_qc>April 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2007</study_first_posted>
  <results_first_submitted>August 19, 2020</results_first_submitted>
  <results_first_submitted_qc>October 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 2, 2020</results_first_posted>
  <last_update_submitted>October 9, 2020</last_update_submitted>
  <last_update_submitted_qc>October 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Mercy Hospital Kansas City</investigator_affiliation>
    <investigator_full_name>Melissa Miller</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>constipation</keyword>
  <keyword>treatment</keyword>
  <keyword>fecal impaction</keyword>
  <keyword>pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyethylene glycol 3350</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A convenience sample of patients aged 1 to 17 years was recruited between December 2006 and May 2009 from a pediatric emergency department.</recruitment_details>
      <pre_assignment_details>There were no significant events that occurred after enrollment and before study arm assignment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Enema</title>
          <description>milk and molasses enema: enema 10 cc/kg per rectum (max 500 cc)then PEG 3350 0.8 gram/kg for maintenance</description>
        </group>
        <group group_id="P2">
          <title>PEG 3350</title>
          <description>PEG 3350: PEG 3350 1.5 gram/kg for disimpaction then 0.8 gram/kg for maintenance</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Enema</title>
          <description>Rectal enema containing mixture of milk and molasses&#xD;
milk and molasses enema: enema 10 cc/kg per rectum (max 500 cc)then PEG 3350 0.8 gram/kg for maintenance</description>
        </group>
        <group group_id="B2">
          <title>PEG 3350</title>
          <description>Medication to be taken orally once each day for three consecutive days&#xD;
PEG 3350: PEG 3350 1.5 gram/kg for disimpaction then 0.8 gram/kg for maintenance</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="39"/>
            <count group_id="B3" value="79"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.8" spread="0.7"/>
                    <measurement group_id="B2" value="6.9" spread="0.7"/>
                    <measurement group_id="B3" value="6.9" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Participants With Main Symptom Improvement</title>
        <description>On day 5, the number of participants who respond &quot;improved&quot; to the question &quot;Has your child's main symptom improved, stayed the same or gotten worse?&quot;</description>
        <time_frame>5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enema</title>
            <description>milk and molasses enema: enema 10 cc/kg per rectum (max 500 cc)then PEG 3350 0.8 gram/kg for maintenance</description>
          </group>
          <group group_id="O2">
            <title>PEG 3350</title>
            <description>PEG 3350: PEG 3350 1.5 gram/kg for disimpaction then 0.8 gram/kg for maintenance</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants With Main Symptom Improvement</title>
          <description>On day 5, the number of participants who respond &quot;improved&quot; to the question &quot;Has your child's main symptom improved, stayed the same or gotten worse?&quot;</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <non_inferiority_desc>Similar to previous studies, the main outcome measure was the change in the child's main symptom. Changes were determined by the question &quot;Has your child's main symptom improved, stayed the same or gotten worse?&quot; The main symptom was defined as the chief complaint identified during the triage process. For analysis, responses were dichotomized into 2 groups: improved/better versus worse/same.</non_inferiority_desc>
            <other_analysis_desc>A χ2 test was used to examine the difference in probabilities of experiencing an outcome between treatment arms and differences were expressed by Mantel-Haenszel common OR estimate with 95% confidence interval (CI).</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Enema</title>
          <description>milk and molasses enema: enema 10 cc/kg per rectum (max 500 cc)then PEG 3350 0.8 gram/kg for maintenance</description>
        </group>
        <group group_id="E2">
          <title>PEG 3350</title>
          <description>PEG 3350: PEG 3350 1.5 gram/kg for disimpaction then 0.8 gram/kg for maintenance</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>treatment failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>More than half of patients who were approached declined participation. A moderate number of patients (29%) were lost to follow-up.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Melissa Miller MD</name_or_title>
      <organization>Children's Mercy Hospitals and Clinics</organization>
      <phone>8162343000</phone>
      <email>mmiller@cmh.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

